Related Experiment Video
Updated: May 16, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Increased arterial stiffness in subjects with impaired fasting glucose
Jean Kyung Paik1, Minjoo Kim, Jung Hyun Kwak
1Yonsei University Research Institute of Science for Aging, Yonsei University, Seoul, Korea.
Aims:
The present study investigated the association between fasting glucose and arterial stiffness in subjects with normal fasting glucose (NFG) and impaired fasting glucose (IFG).
Methods:
The study group consisted of 1043 subjects, including 683 subjects with NFG and 360 subjects with IFG (100≤fasting glucose <126 mg/dL). All subjects were evaluated for glucose, insulin, lipid profiles, high sensitivity C-reactive protein (hs-CRP), malondialdehyde (MDA), 8-epi-prostaglandin F2α (8-epi-PGF2α) and brachial-ankle pulse wave velocity (ba-PWV).
Results:
MDA (P<0.001) and ba-PWV (P<0.001) in the IFG group were higher than those in the NFG group after adjustment for sex, age, BMI, smoking and drinking, waist, blood pressure, serum lipid profiles. Ba-PWV in the IFG group was still higher than that in the NFG group after further adjustment for hs-CRP, MDA, 8-epi-PGF2α (P=0.031). Through multiple linear regression analysis, ba-PWV was found to be independently and positively associated with fasting glucose, age, systolic blood pressure, triglyceride, hs-CRP and insulin and negatively associated with male:female ratio, BMI.
Conclusion:
Arterial stiffness was higher in the IFG group than in subjects with NFG even after adjustment for all confounding variables including hs-CRP and oxidative stress markers. In addition, fasting glucose and insulin were positively and independently associated with the ba-PWV in non-diabetic healthy adults.
Related Concept Videos
Hyperglycemia
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes: Symptoms, Diagnosis, and Complications
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Type I Diabetes III: Clinical Manifestations
Type II Diabetes II: Pathophysiology

